72% Drug Failure: Pharma’s 2026 Reckoning

Listen to this article · 8 min listen

It’s a brutal statistic: 72% of cardiovascular drugs that enter Phase 1 clinical trials will never be approved. That number should be a wake-up call for the entire pharma industry, forcing us to ask what’s fundamentally wrong with our development model. We pour billions into R&D, yet promising compounds keep hitting a wall in later-stage trials. This isn’t just bad luck. It’s a systemic problem telling us our strategies for finding and validating new therapies are broken.

Key Takeaways

  • The animal models we use in pre-clinical studies just don’t predict what will happen in humans, which is why so many cardiovascular drugs die in Phase 2.
  • Using biomarkers early on to screen patients and design better trials is a proven way to dramatically increase the odds of a drug succeeding.
  • Adaptive trials let us change protocols on the fly using interim data, which can save a drug that looks like it’s on the fence.
  • To de-risk early-stage development, partnerships between academia, biotech, and big pharma are no longer optional, they’re the only way to pool enough money and brainpower.
  • What happens after a drug is approved matters. We’re learning to use real-world evidence from post-market surveillance to fine-tune how we use drugs and even find new uses for them.

The Disconnect in Pre-Clinical Predictive Power

The numbers in Phase 2 are where things really fall apart. We see an attrition rate over 50% for novel molecular entities because what works in the lab simply doesn’t hold up in people. Animal models are our first line of defense for screening, but their predictive power for the human cardiovascular system is notoriously weak. I’ve seen it myself: compounds that look like a sure thing in cell cultures or rodent models, which the Associated Press recently noted show big promise for heart failure, end up having minimal effect or causing unexpected toxicities once they get into human trials.

Our models themselves are the limitation, not the effort we put into them. Animal physiology has similarities to ours, but important differences in metabolism, immune response, and how a disease actually progresses can give us completely misleading results. We’re trying to model complex, multi-factorial cardiovascular diseases where a person’s genetics, diet, and environment all play a role, something that’s almost impossible to perfectly replicate in a lab. So, no matter how careful the pre-clinical work is, we’re always carrying a huge amount of uncertainty into Phase 1, knowing the drug could behave completely differently in a person.

Underestimated Value of Biomarker Integration

One of our biggest missed opportunities is the slow adoption of strong biomarkers in early-stage cardiovascular drug development. We have data from Reuters Health showing that trials using validated biomarkers for patient selection have a 2 to 3 times higher success rate in later phases. Yet we keep running studies with huge, undifferentiated patient groups and relying on old-school clinical endpoints that take forever to show up. It’s just inefficient and expensive.

Take new anti-thrombotic agents, for example. Waiting for major adverse cardiovascular events (MACE) as the main endpoint takes a long time and a lot of patients. Instead, we should be using biomarkers like D-dimer levels or specific platelet activation markers right from the start to stratify patients. This lets you find the people who are actually likely to benefit from the drug, which cleans up the data and makes it easier to see a real effect. Finding that signal in the noise means you can run a smaller, faster trial. Biomarkers enhance clinical observation with precise, measurable biological data that tells you if you’re on the right track much earlier.

The Persistent Challenge of Patient Recruitment and Retention

It’s a logistical nightmare that kills studies: a Journal of Clinical Trials analysis found that up to 30% of cardiovascular trials get seriously delayed or shut down because they can’t find or keep enough patients. This operational failure directly guts the statistical power of a trial and makes the results less reliable. If you can’t get a diverse group of patients to stick with the study, you have no idea if the drug will actually work in the real world.

It’s not hard to see why it’s so difficult. Patients with cardiovascular issues are often juggling other health problems, a complicated list of medications, and the real-world hassle of getting to a clinic over and over. Then you add in overly complex trial protocols and the fact that they’re being recruited for multiple studies at once. I’ve seen that the trials that actually succeed are the ones that respect the patient’s time, offering flexible appointments, remote monitoring, and clear communication. Frankly, we’ve expected patients to jump through hoops without giving them the support they need.

72%
Cardiovascular Drug Failure Rate
50%+
Phase 2 Attrition Rate for Novel Entities
2-3x
Higher Success with Biomarkers
30%
Trials Delayed/Terminated by Recruitment Issues

Funding Gaps for Repurposing Existing Drugs

We’re obsessed with finding novel compounds, but we’re ignoring a huge source of potential therapies right under our noses. Less than 10% of new funding for cardiovascular drug development is explicitly allocated to drug repurposing initiatives. This is a massive strategic error. As NPR Health Shots has reported, taking drugs already approved for other conditions and testing them for cardiovascular use is a shortcut. Their safety profiles are known, dramatically cutting down development time and cost.

The industry’s focus on blockbuster novel drugs means we miss obvious wins. Everyone knows the story of sildenafil (Viagra), it was being studied for angina before its famous side effect created a whole new market, and it’s now also used for pulmonary hypertension. How many other drugs are sitting on the shelf with mechanisms that could work for other cardiovascular problems? We need to systematically look for them. The development path is faster and the risk is far lower, which means we could deliver effective treatments to patients years sooner than a brand new molecule. It’s time to stop thinking that only “new” drugs are valuable.

The Overlooked Role of Real-World Evidence

For decades, the randomized controlled trial (RCT) has been the gold standard, and for good reason. But we’re sitting on a mountain of real-world evidence (RWE) that we’re failing to properly use in our post-trial assessments. While RCTs are essential for proving a drug works under ideal, controlled conditions, they don’t tell you what happens in the messy reality of clinical practice. For instance, a recent study in The BMJ showed that some anti-hypertensive drugs perform very differently in the real world compared to the highly selected cohorts in their original trials.

RCTs are still vital for approval, but ignoring the data available from electronic health records, insurance claims, and patient registries is a huge mistake. RWE is where you find insights on long-term safety, see how your drug stacks up against competitors, and even spot new potential uses or rare side effects that a short, controlled trial would never catch. It lets you see the drug’s performance throughout its entire lifecycle. Yes, there are methodological hurdles and regulatory caution, but we have the analytical tools to handle that now. The payoff in terms of patient safety and optimizing treatment is too big to let old habits get in the way.

That 72% failure rate isn’t just a number. It’s a symptom of a broken pipeline. We can’t keep doing things the same way and expect different results. Fixing this means making specific changes: stop relying on bad pre-clinical models, actually use the biomarkers we know can predict success, design trials that people can actually complete, put real money into repurposing old drugs, and start trusting real-world evidence. If we don’t, we’re just going to keep wasting billions on drugs that are doomed to fail.

What is the primary reason for cardiovascular drug failures in clinical trials?

Failures in Phase 2 usually come down to a drug not working as expected in humans or showing unforeseen toxicity, problems our pre-clinical animal models are just not good at predicting.

How can biomarkers improve the success rate of cardiovascular drug development?

They let you select the right patients for a trial, see who is responding early on, and get objective data on a drug’s effect. All this makes it much more likely you’ll get a clear, positive result.

What role does patient recruitment play in the drug development pipeline?

If you can’t recruit or retain enough patients, trials get delayed, become statistically too weak to prove anything, or get shut down entirely. It’s a direct bottleneck to getting new drugs approved.

Is drug repurposing a viable strategy for cardiovascular diseases?

Absolutely. Investigating existing, approved drugs for new cardiovascular indications is a smart shortcut. Their safety is already known, which dramatically cuts down on development time and money.

Why is real-world evidence becoming more important in cardiovascular drug assessment?

RWE shows how a drug actually performs out in the wild, across all sorts of different patients, not just in the perfect conditions of a clinical trial. It gives you the full story on long-term safety and effectiveness and can even point to new uses.

Editorial Team

The Editorial Team at News Snook is a group of writers and editors who cover the stories shaping their industry. They research each story and publish under a shared desk byline — experts in their fields, working as one team.